Bausch & Lomb announced it has acquired the rights to market a new medication for the treatment of dry eye syndrome. This, yet to be named, medication will improve the quality of tears by promoting the eye’s ability to produce mucin, an essential component of our tears, that is responsible for prolonging the evaporation time.
This medication will be the first of it’s class and the first to focus on improving tear quality instead of quantity. Dosing will be twice a day. Phase 3 clinical trials are to begin by the end of 2013.
While a few years from clinical use this compound will provide a new approach to the treatment of dry eye syndrome..